RHBDF2 and hepatocellular carcinoma: We observed that RHBDF2 overexpression significantly correlated with poorer overall survival (OS) [hazard ratio (HR) = 1.57, P = 0.011], progression‐free survival PFS (HR = 1.6, P = 0.0071) and recurrence‐free survival (RFS) (HR = 1.55, P = 0.0041) in HCC patients, but not with disease‐specific survivial (DSS) (HR = 1.48, P = 0.096) (Fig. 3A–D).